JP2010513262A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513262A5 JP2010513262A5 JP2009540886A JP2009540886A JP2010513262A5 JP 2010513262 A5 JP2010513262 A5 JP 2010513262A5 JP 2009540886 A JP2009540886 A JP 2009540886A JP 2009540886 A JP2009540886 A JP 2009540886A JP 2010513262 A5 JP2010513262 A5 JP 2010513262A5
- Authority
- JP
- Japan
- Prior art keywords
- integer
- ono
- group
- compound
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 4
- 125000002993 cycloalkylene group Chemical group 0.000 claims 4
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 claims 4
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 3
- 206010030043 Ocular hypertension Diseases 0.000 claims 3
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 3
- 201000011190 diabetic macular edema Diseases 0.000 claims 3
- 201000001948 hypertensive retinopathy Diseases 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims 2
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 150000003180 prostaglandins Chemical class 0.000 claims 2
- 208000037822 retinal angiopathy Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims 1
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 208000014139 Retinal vascular disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims 1
- 229960001160 latanoprost Drugs 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 229910052717 sulfur Chemical group 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 229960004605 timolol Drugs 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87028506P | 2006-12-15 | 2006-12-15 | |
| PCT/IB2007/003856 WO2008075155A2 (en) | 2006-12-15 | 2007-12-03 | Carbonic anhydrase inhibitors derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010513262A JP2010513262A (ja) | 2010-04-30 |
| JP2010513262A5 true JP2010513262A5 (enExample) | 2011-01-20 |
Family
ID=39410174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540886A Withdrawn JP2010513262A (ja) | 2006-12-15 | 2007-12-03 | カルボニックアンヒドラーゼ阻害剤誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100063035A1 (enExample) |
| EP (1) | EP2097421A2 (enExample) |
| JP (1) | JP2010513262A (enExample) |
| CA (1) | CA2671137A1 (enExample) |
| WO (1) | WO2008075155A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9808531B2 (en) * | 2015-09-22 | 2017-11-07 | Graybug Vision, Inc. | Compounds and compositions for the treatment of ocular disorders |
| CA3056923A1 (en) | 2017-03-23 | 2018-09-27 | Graybug Vision, Inc. | Drugs and compositions for the treatment of ocular disorders |
| JP2020519585A (ja) | 2017-05-10 | 2020-07-02 | グレイバグ ビジョン インコーポレイテッド | 医学療法のための延長放出マイクロ粒子及びその懸濁液 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE239468T1 (de) * | 1996-02-26 | 2003-05-15 | Advanced Res & Tech Inst | Verwendung von carbonanhydrase-hemmern zur behandlung von makulär-ödemen |
| CA2294343A1 (en) * | 1997-06-26 | 1999-01-07 | Merck & Co., Inc. | Method for optimizing retinal and optic nerve health |
| WO2005068421A1 (en) * | 2004-01-05 | 2005-07-28 | Nicox, S.A. | Prostaglandin nitrooxyderivatives |
| WO2006052899A2 (en) * | 2004-11-08 | 2006-05-18 | Nitromed, Inc. | Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders |
| EP1855688A4 (en) * | 2005-02-24 | 2011-09-14 | Nicox Sa | NON-STAINED OXIDE DIURETIC COMPOUNDS, COMPOSITIONS AND USE PROCESSES |
-
2007
- 2007-12-03 JP JP2009540886A patent/JP2010513262A/ja not_active Withdrawn
- 2007-12-03 US US12/516,460 patent/US20100063035A1/en not_active Abandoned
- 2007-12-03 EP EP07849012A patent/EP2097421A2/en not_active Withdrawn
- 2007-12-03 WO PCT/IB2007/003856 patent/WO2008075155A2/en not_active Ceased
- 2007-12-03 CA CA002671137A patent/CA2671137A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2400070T3 (es) | Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos | |
| RU2007124329A (ru) | ПРОИЗВОДНЫЕ 5-ГИДРОКСИБЕНЗОТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНОРЕЦЕПТОРОВ | |
| RU2010116708A (ru) | Бициклическое производное гамма-аминокислоты | |
| CN105848650A (zh) | 促进吸烟停止 | |
| JP2013519653A5 (enExample) | ||
| JP2011510965A (ja) | 高眼圧症の治療のためのジフルオロビフェニルアミド誘導体 | |
| JP2007505931A5 (enExample) | ||
| RU2009128968A (ru) | Производные изосорбидмононитрата для лечения повышенной внутриглазной гипертензии | |
| RU2004122427A (ru) | Пирролидин-2-оны в качестве ингибиторов фактора ха | |
| JP2009525970A5 (enExample) | ||
| CN111328278A (zh) | 经皮制剂 | |
| JP2010513262A5 (enExample) | ||
| CA2491612A1 (en) | 4-'7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents | |
| KR20140091457A (ko) | 녹내장 및 고안압증 치료용 아데노신 a1 작용제 | |
| RU2011108485A (ru) | Новые (поли)аминоалкиламиноалкиламидные, алкилмочевинные или алкилсульфонамидные производные эпиподофиллотоксина, способ их получения и их применение в терапии в качестве противораковых средств | |
| CA2453433A1 (en) | Methods of use for novel sulfur containing organic nitrate compounds | |
| JP2019534296A5 (enExample) | ||
| TW200531967A (en) | Aqueous composition comprising thiazole derivative | |
| JP2004520267A5 (enExample) | ||
| JP2004506010A5 (enExample) | ||
| RU2005130992A (ru) | Производные сложноэфирных липидов нуклеотидов | |
| JP2004529177A5 (enExample) | ||
| JP2010509240A5 (enExample) | ||
| JP2016539148A5 (enExample) | ||
| JP2010513262A (ja) | カルボニックアンヒドラーゼ阻害剤誘導体 |